Comment pouvons-nous vous aider?

  • Passion for peptides – The people behind Pepscan

    “Our drive to move forward combined with a positive spirit and creativity are important assets” “As an employee of Pepscan for almost 15 years, I have worked on several challenges regarding Pepscan’s continuous drive for development and improvement. I’m glad that we also overcame our latest challenge: providing our customers with on-schedule and high-quality deliveries while working under COVID-19 guidelines,” says Richard van Duinkeren, Team Lead Analytics at Pepscan. Keeping up the pace and delivery schedules As soon as the …

  • COVID-19 Services – Peptide libraries – A powerful tool for vaccine lead finding

    Benefit from an unprecedented choice of library sizes and rapid delivery times Peptide libraries are widely applied as a powerful tool in biological research. Peptide libraries provide a rapid and cost-effective solution for a broad range of bioactivity-screening purposes, like identification of critical bioactive peptides which could serve, for example, as lead for a new COVID-19-related vaccine. Pepscan is the founder of peptide library technology and has over 25 years of experience in designing, synthesizing, and utilizing custom peptide libraries. …

  • Pepscan COVID-19 Update – Facility Operational

    We would like to inform you that the Pepscan facility is operational. This allows us to proceed serving and supporting scientists in their work on amongst others diagnostic and vaccine related COVID-19 projects and treatment of cancer patients with personalized peptide vaccines. By implementing a shift-schedule and additional precautionary measures to minimize physical interaction amongst our staff, we are able to continue the production and delivery of R&D and clinical peptides so far. Our sales team works offsite, but strives …

  • Pepscan Webinar: Next generation peptide discovery

    Learn about Pepscan’s phage display technology used to discover highly constrained peptides with enhanced affinity, selectivity and proteolytic stability. April 2nd – 16.00 CEST – 10.00 ET – 7.00 PT Register here We invite you to join our upcoming webinar featuring Pepscan experts Prof. Peter Timmerman and Dr. Michael Goldflam sharing their expertise on de novo discovery of the best peptide binders for your target protein of interest.  This webinar will discuss Pepscan’s proprietary phage display CLIPSTM technology platform, which …

  • Pepscan Case – Use of 3D-structured peptides mimicking monoclonal antibody binding site to develop VEGF targeting vaccine

    Therapeutic targeting of the VEGF signaling axis by the VEGF neutralizing monoclonal antibody bevacizumab has clearly demonstrated clinical benefit in cancer patients. To improve this strategy using a polyclonal approach, a vaccine targeting VEGF was developed for medical oncology using 3D-structured peptides that mimic the bevacizumab binding site. “Before the start of this RVO-funded project a small research group, including myself, had developed a general approach to protein-mimics using scaffold-technology. We wanted to apply this approach to the mimicry of …

  • Passion for peptides – The people behind Pepscan

    “Being able to discover and develop new therapeutics is what makes me passionate about my work!” “In the upcoming period I would like to combine my knowledge and experience with Pepscan’s Phage Display technology and team, to take my new employer’s Peptide Discovery platform to the next level, aiming to boost drug discovery and development,” says Sangram Kale, who recently started as Scientist at Pepscan. Sangram originally comes from India, where he completed his Master and PhD degrees in Organic …

  • Antibody epitope mapping – A crucial and inevitable step in therapeutic antibody development

    Why Pepscan is the provider of epitope mapping services in 58% of last year’s European patent publications Mapping the epitopes of an antibody is an inevitable step in therapeutic antibody development. Epitope mapping not only serves intellectual property purposes, but also provides the data needed for antibody selection and characterization and gives the information needed for FDA and EMA regulatory filings. Dennis Flierman and Martin Ham visited the 2019 Antibody Engineering & Therapeutics Conference in San Diego and spotted the …

  • Surpassing expectations via joint innovation

    Developing the next generation hydrogel using Pepscan’s RGD bicyclic peptides Pepscan and 13 other partners participated in the Horizon 2020 – Marie Skodowska-Curie project BIOGEL’s consortium. “Our primary task was to fabricate cell-specific bicyclic peptides that can be utilized to modify the hydrogels with specific integrin-binding domains, in this case RGD, to direct cells,” says Peter Timmerman, CSO at Pepscan. Paul Kouwer, Assistant Professor at Radboud University, adds: “Our preliminary results show a thousand-fold increase in cell binding. You can …

  • Pepscan at Immuno-Oncology Summit/TMB & Neoantigen Stream

    “A great opportunity to share our knowledge and experience!” The battle to outsmart cancer isn’t won yet. Scientists are continuously looking for new and better approaches to tackle this disease. Cancer treatment with a personalized neoantigen peptide vaccine is a rising star among these approaches. Recently Pepscan has positioned itself as a critical partner in several collaborative clinical trials with these personalized anti-cancer vaccines. “The neoantigen supply chain is focused on efficiency and speed. To meet this need, we have …

  • Passion for peptides – The people behind Pepscan

    “I’m a generalist working at the interface of chemistry, biology and physics” Velten Horn started working for Pepscan at the beginning of this year. “Shortly after joining Pepscan I was awarded my PhD at Leiden University. There I studied protein-protein and peptide-protein interactions on a structural level with a wide range of biophysical and computational techniques.” Velten recently transferred to Pepscan’s Department of Epitope Mapping working as a Scientist. “It is a perfect fit,” he recalls. Velten is originally from …

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the Pepscan website. However, if you would like to, you can change your cookie settings at any time in your browser.
Cookie Policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies